Identification

Name
Etoperidone
Accession Number
DB09194
Type
Small Molecule
Groups
Withdrawn
Description

Etoperidone is an atypical antidepressant introduced in Europe in 1977. It is a phenylpiperazine-substituted triazole derivative with a composition that classifies it as an analog of tradozone and presents a similar pharmacological profile.[6] Etoperidone was developed by Angelini Francesco ACRAF and even nowadays, there is uncertanty if this drug ever reached the market.[2]

Structure
Thumb
Synonyms
Not Available
External IDs
ST-1191
Product Ingredients
IngredientUNIICASInChI Key
Etoperidone hydrochloride2FSU2FR80JNot AvailableBHKPQZVLIZKSAG-UHFFFAOYSA-N
International/Other Brands
Axiomin (Promeco) / Depracer (L. Lepori, Lda.) / Etonin / Etoran (II Dong) / Staff (Sigma-Tau) / Tropene (Degussa)
Categories
UNII
KAI6MVO39Z
CAS number
52942-31-1
Weight
Average: 377.92
Monoisotopic: 377.1982382
Chemical Formula
C19H28ClN5O
InChI Key
IZBNNCFOBMGTQX-UHFFFAOYSA-N
InChI
InChI=1S/C19H28ClN5O/c1-3-18-21-25(19(26)24(18)4-2)10-6-9-22-11-13-23(14-12-22)17-8-5-7-16(20)15-17/h5,7-8,15H,3-4,6,9-14H2,1-2H3
IUPAC Name
1-{3-[4-(3-chlorophenyl)piperazin-1-yl]propyl}-3,4-diethyl-4,5-dihydro-1H-1,2,4-triazol-5-one
SMILES
CCN1C(=O)N(CCCN2CCN(CC2)C2=CC=CC(Cl)=C2)N=C1CC

Pharmacology

Indication

Etoperidone has been studied for the treatment of depression[8], tremors in Parkinson, extrapyramidal symptoms[11] and male impotence[12]. It is not certain if it was ever approved and marketed but its current status is withdrawn.

Structured Indications
Not Available
Pharmacodynamics

Etoperidone has a biphasic effect on the central transmission of serotonin.[6] It presents the capacity to inhibit serotonin receptor but also to inhibit the reuptake of serotonin, norepinephrine and dopamine.[7] As part of its actions, etoperidone also inhibits the α-adrenergic receptors which directly corresponds to the sedative and cardiovascular effects.[6, 9] The presence of both effects caused that the effective dose of etoperidone was poorly tolerated thus, efforts have been made to separate the serotonergic and adrenergic functions in order to generate etoperidone-derivatives like nefazodone.[9]

Mechanism of action

The activity of etoperidone is made mainly by its major metabolite 1-(3'-chlorophenyl)piperazine (mCPP). mCPP binds with different affinity to most of the serotonergic receptors and adrenergic receptors. This metabolite is an agonist of 5-HT2c and an antagonist of 5-HT2a. Part of etoperidone structure contibutes to the activity in the α-adrenergic receptors.[9]

TargetActionsOrganism
UAlpha-1 adrenergic receptors
antagonist
Human
UAlpha-2 adrenergic receptors
antagonist
Human
UD(2) dopamine receptor
antagonist
Human
UHistamine H1 receptor
antagonist
Human
UMuscarinic acetylcholine receptor
antagonist
Human
A5-hydroxytryptamine receptor 2A
antagonist
Human
A5-hydroxytryptamine receptor 2C
agonist
Human
Absorption

The absorption and bioavailability is highly variable between individuals and can be as low as 12%. The lower bioavailability is explained due to its high metabolism.[5] The mean time to peak plasma concentration is ranged from 1.4-4.8 hours.[10]

Volume of distribution

The high protein binding presented in etoperidone modulates its volume of distribution to a range of 0.23 to 0.69 L/kg.[13]

Protein binding

Etoperidone presents an extensive plasma protein binding.[13]

Metabolism

Etoperidone is highly metabolized and it forms 21 different metabolites that can be found in plasma, urine and faeces. The metabolism of etoperidone is thought to be related to 5 different reaction pathways that are alkyl oxidation, piperazinyl oxidation, N-dealkylation, phenyl hydroxylation and conjugation.[4]

Route of elimination

The elimination of an oral dose of etoperidone presents a division of 78.8% found in urine and 9.6% found in faeces. On the elimination route, less than 0.01% of the etoperidone dose is represented by the unchanged drug while the rest is formed by 21 different metabolites.[4]

Half life

After oral administration of etoperidone the terminal half-life was 21.7 hours.[4]

Clearance

The apparent clearance of etoperidone was 1.01 ml/min.[4]

Toxicity

Etoperidone presented major cardiovascular effects recorded as abnormal electrocardiogram, changes in blood pressure and even cardiac arrest. From the changes in blood pressure hypotension was the primary effect. These cardiovascular reactions are consistent with its effect to catecholamines.[5]

Affected organisms
  • Humans and other mammals
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
7-NitroindazoleThe risk or severity of adverse effects can be increased when 7-Nitroindazole is combined with Etoperidone.Experimental
7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline may increase the serotonergic activities of Etoperidone.Experimental
AcarboseEtoperidone may increase the hypoglycemic activities of Acarbose.Approved, Investigational
AcebutololThe serum concentration of Acebutolol can be increased when it is combined with Etoperidone.Approved
AcenocoumarolEtoperidone may increase the anticoagulant activities of Acenocoumarol.Approved
AcepromazineThe risk or severity of adverse effects can be increased when Acepromazine is combined with Etoperidone.Approved, Vet Approved
AceprometazineThe risk or severity of adverse effects can be increased when Aceprometazine is combined with Etoperidone.Approved
Acetylsalicylic acidEtoperidone may increase the antiplatelet activities of Acetylsalicylic acid.Approved, Vet Approved
AdipiplonThe risk or severity of adverse effects can be increased when Adipiplon is combined with Etoperidone.Investigational
AgomelatineThe risk or severity of adverse effects can be increased when Agomelatine is combined with Etoperidone.Approved, Investigational
AlaproclateEtoperidone may increase the serotonergic activities of Alaproclate.Experimental
AlbiglutideEtoperidone may increase the hypoglycemic activities of Albiglutide.Approved
AlfaxaloneThe risk or severity of adverse effects can be increased when Alfaxalone is combined with Etoperidone.Vet Approved
AlfentanilAlfentanil may increase the serotonergic activities of Etoperidone.Approved, Illicit
AllopregnanoloneThe risk or severity of adverse effects can be increased when Allopregnanolone is combined with Etoperidone.Investigational
AlogliptinEtoperidone may increase the hypoglycemic activities of Alogliptin.Approved
AlphacetylmethadolAlphacetylmethadol may increase the serotonergic activities of Etoperidone.Experimental, Illicit
AlphaprodineAlphaprodine may increase the serotonergic activities of Etoperidone.Illicit
AlprazolamThe risk or severity of adverse effects can be increased when Alprazolam is combined with Etoperidone.Approved, Illicit, Investigational
AlprenololThe serum concentration of Alprenolol can be increased when it is combined with Etoperidone.Approved, Withdrawn
AmisulprideThe risk or severity of adverse effects can be increased when Amisulpride is combined with Etoperidone.Approved, Investigational
AmitriptylineThe risk or severity of adverse effects can be increased when Amitriptyline is combined with Etoperidone.Approved
AmobarbitalThe risk or severity of adverse effects can be increased when Amobarbital is combined with Etoperidone.Approved, Illicit
AmoxapineEtoperidone may increase the serotonergic activities of Amoxapine.Approved
AmperozideThe risk or severity of adverse effects can be increased when Amperozide is combined with Etoperidone.Experimental
AmphetamineThe risk or severity of adverse effects can be increased when Etoperidone is combined with Amphetamine.Approved, Illicit
AripiprazoleThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Etoperidone.Approved, Investigational
ArotinololThe serum concentration of Arotinolol can be increased when it is combined with Etoperidone.Approved, Investigational
ArticaineThe risk or severity of adverse effects can be increased when Articaine is combined with Etoperidone.Approved
AsenapineThe risk or severity of adverse effects can be increased when Asenapine is combined with Etoperidone.Approved
AtenololThe serum concentration of Atenolol can be increased when it is combined with Etoperidone.Approved
AzaperoneThe risk or severity of adverse effects can be increased when Azaperone is combined with Etoperidone.Investigational, Vet Approved
AzelastineThe risk or severity of adverse effects can be increased when Azelastine is combined with Etoperidone.Approved
BaclofenThe risk or severity of adverse effects can be increased when Baclofen is combined with Etoperidone.Approved
BarbitalThe risk or severity of adverse effects can be increased when Barbital is combined with Etoperidone.Illicit
BefunololThe serum concentration of Befunolol can be increased when it is combined with Etoperidone.Experimental
BendroflumethiazideEtoperidone may increase the hyponatremic activities of Bendroflumethiazide.Approved
BenmoxinBenmoxin may increase the serotonergic activities of Etoperidone.Withdrawn
BenperidolThe risk or severity of adverse effects can be increased when Benperidol is combined with Etoperidone.Investigational
BenzocaineThe risk or severity of adverse effects can be increased when Benzocaine is combined with Etoperidone.Approved
Benzyl alcoholThe risk or severity of adverse effects can be increased when Benzyl alcohol is combined with Etoperidone.Approved
BetaxololThe serum concentration of Betaxolol can be increased when it is combined with Etoperidone.Approved
BevantololThe serum concentration of Bevantolol can be increased when it is combined with Etoperidone.Approved
BezitramideBezitramide may increase the serotonergic activities of Etoperidone.Experimental, Illicit, Withdrawn
BisoprololThe serum concentration of Bisoprolol can be increased when it is combined with Etoperidone.Approved
BopindololThe serum concentration of Bopindolol can be increased when it is combined with Etoperidone.Approved
BrexpiprazoleThe risk or severity of adverse effects can be increased when Brexpiprazole is combined with Etoperidone.Approved
BrimonidineThe risk or severity of adverse effects can be increased when Brimonidine is combined with Etoperidone.Approved
BrofaromineThe risk or severity of adverse effects can be increased when Etoperidone is combined with Brofaromine.Experimental
BromazepamThe risk or severity of adverse effects can be increased when Bromazepam is combined with Etoperidone.Approved, Illicit
BromisovalThe risk or severity of adverse effects can be increased when Bromisoval is combined with Etoperidone.Experimental
BromocriptineEtoperidone may increase the hypoglycemic activities of Bromocriptine.Approved, Investigational
BromperidolThe risk or severity of adverse effects can be increased when Bromperidol is combined with Etoperidone.Investigational
BrompheniramineThe risk or severity of adverse effects can be increased when Brompheniramine is combined with Etoperidone.Approved
BrotizolamThe risk or severity of adverse effects can be increased when Brotizolam is combined with Etoperidone.Approved, Investigational, Withdrawn
BucindololThe serum concentration of Bucindolol can be increased when it is combined with Etoperidone.Investigational
BufuralolThe serum concentration of Bufuralol can be increased when it is combined with Etoperidone.Experimental, Investigational
BupivacaineThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Etoperidone.Approved, Investigational
BupranololThe serum concentration of Bupranolol can be increased when it is combined with Etoperidone.Approved
BuprenorphineBuprenorphine may increase the serotonergic activities of Etoperidone.Approved, Illicit, Investigational, Vet Approved
BuspironeBuspirone may increase the serotonergic activities of Etoperidone.Approved, Investigational
ButabarbitalThe risk or severity of adverse effects can be increased when Butabarbital is combined with Etoperidone.Approved, Illicit
ButacaineThe risk or severity of adverse effects can be increased when Butacaine is combined with Etoperidone.Vet Approved
ButalbitalThe risk or severity of adverse effects can be increased when Butalbital is combined with Etoperidone.Approved, Illicit
ButambenThe risk or severity of adverse effects can be increased when Butamben is combined with Etoperidone.Approved
ButethalThe risk or severity of adverse effects can be increased when Butethal is combined with Etoperidone.Approved, Illicit
ButorphanolButorphanol may increase the serotonergic activities of Etoperidone.Approved, Illicit, Vet Approved
CanagliflozinEtoperidone may increase the hypoglycemic activities of Canagliflozin.Approved
CanertinibThe risk or severity of adverse effects can be increased when Canertinib is combined with Etoperidone.Investigational
CarbamazepineThe metabolism of Carbamazepine can be decreased when combined with Etoperidone.Approved, Investigational
CarbinoxamineThe risk or severity of adverse effects can be increased when Carbinoxamine is combined with Etoperidone.Approved
CarfentanilCarfentanil may increase the serotonergic activities of Etoperidone.Illicit, Investigational, Vet Approved
CarisoprodolThe risk or severity of adverse effects can be increased when Carisoprodol is combined with Etoperidone.Approved
CaroxazoneCaroxazone may increase the serotonergic activities of Etoperidone.Withdrawn
CarteololThe serum concentration of Carteolol can be increased when it is combined with Etoperidone.Approved
CarvedilolThe serum concentration of Carvedilol can be increased when it is combined with Etoperidone.Approved, Investigational
CelecoxibEtoperidone may increase the antiplatelet activities of Celecoxib.Approved, Investigational
CeliprololThe serum concentration of Celiprolol can be increased when it is combined with Etoperidone.Approved, Investigational
CetirizineThe risk or severity of adverse effects can be increased when Cetirizine is combined with Etoperidone.Approved
Chloral hydrateThe risk or severity of adverse effects can be increased when Chloral hydrate is combined with Etoperidone.Approved, Illicit, Vet Approved
ChlordiazepoxideThe risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Etoperidone.Approved, Illicit
ChlormezanoneThe risk or severity of adverse effects can be increased when Chlormezanone is combined with Etoperidone.Approved, Investigational, Withdrawn
ChloroprocaineThe risk or severity of adverse effects can be increased when Chloroprocaine is combined with Etoperidone.Approved
ChlorothiazideEtoperidone may increase the hyponatremic activities of Chlorothiazide.Approved, Vet Approved
ChlorphenamineThe risk or severity of adverse effects can be increased when Chlorphenamine is combined with Etoperidone.Approved
ChlorpromazineThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Etoperidone.Approved, Vet Approved
ChlorpropamideEtoperidone may increase the hypoglycemic activities of Chlorpropamide.Approved
ChlorprothixeneThe risk or severity of adverse effects can be increased when Chlorprothixene is combined with Etoperidone.Approved, Investigational, Withdrawn
ChlorthalidoneEtoperidone may increase the hyponatremic activities of Chlorthalidone.Approved
ChlorzoxazoneThe risk or severity of adverse effects can be increased when Chlorzoxazone is combined with Etoperidone.Approved
CimetidineThe metabolism of Etoperidone can be decreased when combined with Cimetidine.Approved
CinchocaineThe risk or severity of adverse effects can be increased when Cinchocaine is combined with Etoperidone.Approved, Vet Approved
CitalopramEtoperidone may increase the serotonergic activities of Citalopram.Approved
ClemastineThe risk or severity of adverse effects can be increased when Clemastine is combined with Etoperidone.Approved
ClidiniumThe risk or severity of adverse effects can be increased when Clidinium is combined with Etoperidone.Approved
ClobazamThe risk or severity of adverse effects can be increased when Clobazam is combined with Etoperidone.Approved, Illicit
clomethiazoleThe risk or severity of adverse effects can be increased when clomethiazole is combined with Etoperidone.Investigational
ClomipramineEtoperidone may increase the serotonergic activities of Clomipramine.Approved, Vet Approved
ClonazepamThe risk or severity of adverse effects can be increased when Clonazepam is combined with Etoperidone.Approved, Illicit
ClonidineThe risk or severity of adverse effects can be increased when Clonidine is combined with Etoperidone.Approved
ClopenthixolThe risk or severity of adverse effects can be increased when Clopenthixol is combined with Etoperidone.Experimental
CloranololThe serum concentration of Cloranolol can be increased when it is combined with Etoperidone.Experimental
ClorazepateThe risk or severity of adverse effects can be increased when Clorazepate is combined with Etoperidone.Approved, Illicit
ClorindioneEtoperidone may increase the anticoagulant activities of Clorindione.Experimental
ClothiapineThe risk or severity of adverse effects can be increased when Clothiapine is combined with Etoperidone.Experimental
ClozapineThe serum concentration of Clozapine can be increased when it is combined with Etoperidone.Approved
CocaineThe risk or severity of adverse effects can be increased when Cocaine is combined with Etoperidone.Approved, Illicit
CodeineCodeine may increase the serotonergic activities of Etoperidone.Approved, Illicit
CyclizineThe risk or severity of adverse effects can be increased when Cyclizine is combined with Etoperidone.Approved
CyclobenzaprineThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Etoperidone.Approved
CyclopenthiazideEtoperidone may increase the hyponatremic activities of Cyclopenthiazide.Experimental
CyproheptadineThe therapeutic efficacy of Etoperidone can be decreased when used in combination with Cyproheptadine.Approved
DantroleneThe risk or severity of adverse effects can be increased when Dantrolene is combined with Etoperidone.Approved
DapagliflozinEtoperidone may increase the hypoglycemic activities of Dapagliflozin.Approved
DapiprazoleThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Etoperidone.Approved
DapoxetineEtoperidone may increase the serotonergic activities of Dapoxetine.Investigational
DeramciclaneThe risk or severity of adverse effects can be increased when Deramciclane is combined with Etoperidone.Investigational
DesfluraneThe risk or severity of adverse effects can be increased when Desflurane is combined with Etoperidone.Approved
DesipramineThe risk or severity of adverse effects can be increased when Desipramine is combined with Etoperidone.Approved
DesloratadineThe risk or severity of adverse effects can be increased when Desloratadine is combined with Etoperidone.Approved, Investigational
DesmopressinThe risk or severity of adverse effects can be increased when Etoperidone is combined with Desmopressin.Approved
DetomidineThe risk or severity of adverse effects can be increased when Detomidine is combined with Etoperidone.Vet Approved
DexbrompheniramineThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Etoperidone.Approved
DexmedetomidineThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Etoperidone.Approved, Vet Approved
DextromethorphanEtoperidone may increase the serotonergic activities of Dextromethorphan.Approved
DextromoramideDextromoramide may increase the serotonergic activities of Etoperidone.Experimental, Illicit
DextropropoxypheneDextropropoxyphene may increase the serotonergic activities of Etoperidone.Approved, Illicit, Investigational, Withdrawn
DezocineDezocine may increase the serotonergic activities of Etoperidone.Approved, Investigational
DiazepamThe risk or severity of adverse effects can be increased when Diazepam is combined with Etoperidone.Approved, Illicit, Vet Approved
DicoumarolEtoperidone may increase the anticoagulant activities of Dicoumarol.Approved
Diethyl etherThe risk or severity of adverse effects can be increased when Diethyl ether is combined with Etoperidone.Experimental
DifenoxinThe risk or severity of adverse effects can be increased when Difenoxin is combined with Etoperidone.Approved, Illicit
DihydrocodeineDihydrocodeine may increase the serotonergic activities of Etoperidone.Approved, Illicit
DihydroetorphineDihydroetorphine may increase the serotonergic activities of Etoperidone.Experimental, Illicit
DihydromorphineDihydromorphine may increase the serotonergic activities of Etoperidone.Experimental, Illicit
DimenhydrinateThe risk or severity of adverse effects can be increased when Dimenhydrinate is combined with Etoperidone.Approved
DiphenadioneEtoperidone may increase the anticoagulant activities of Diphenadione.Experimental
DiphenhydramineThe risk or severity of adverse effects can be increased when Diphenhydramine is combined with Etoperidone.Approved
DiphenoxylateDiphenoxylate may increase the serotonergic activities of Etoperidone.Approved, Illicit
DisopyramideEtoperidone may increase the hypoglycemic activities of Disopyramide.Approved
DixyrazineThe risk or severity of adverse effects can be increased when Dixyrazine is combined with Etoperidone.Experimental
DoramectinThe risk or severity of adverse effects can be increased when Doramectin is combined with Etoperidone.Vet Approved
DosulepinThe serum concentration of Dosulepin can be increased when it is combined with Etoperidone.Approved
DoxepinThe risk or severity of adverse effects can be increased when Doxepin is combined with Etoperidone.Approved
DoxylamineThe risk or severity of adverse effects can be increased when Doxylamine is combined with Etoperidone.Approved, Vet Approved
DPDPEDPDPE may increase the serotonergic activities of Etoperidone.Experimental
DroperidolThe risk or severity of adverse effects can be increased when Droperidol is combined with Etoperidone.Approved, Vet Approved
DrotebanolThe risk or severity of adverse effects can be increased when Drotebanol is combined with Etoperidone.Experimental, Illicit
DulaglutideEtoperidone may increase the hypoglycemic activities of Dulaglutide.Approved
DyclonineThe risk or severity of adverse effects can be increased when Dyclonine is combined with Etoperidone.Approved
EcgonineThe risk or severity of adverse effects can be increased when Ecgonine is combined with Etoperidone.Experimental, Illicit
EcopipamThe risk or severity of adverse effects can be increased when Ecopipam is combined with Etoperidone.Investigational
EfavirenzThe risk or severity of adverse effects can be increased when Efavirenz is combined with Etoperidone.Approved, Investigational
EltanoloneThe risk or severity of adverse effects can be increased when Eltanolone is combined with Etoperidone.Investigational
EmpagliflozinEtoperidone may increase the hypoglycemic activities of Empagliflozin.Approved
EnfluraneThe risk or severity of adverse effects can be increased when Enflurane is combined with Etoperidone.Approved, Investigational, Vet Approved
EntacaponeThe risk or severity of adverse effects can be increased when Entacapone is combined with Etoperidone.Approved, Investigational
EpanololThe serum concentration of Epanolol can be increased when it is combined with Etoperidone.Experimental
EscitalopramEtoperidone may increase the serotonergic activities of Escitalopram.Approved, Investigational
EsmololThe serum concentration of Esmolol can be increased when it is combined with Etoperidone.Approved
EstazolamThe risk or severity of adverse effects can be increased when Estazolam is combined with Etoperidone.Approved, Illicit
EszopicloneThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Etoperidone.Approved
EthanolThe risk or severity of adverse effects can be increased when Ethanol is combined with Etoperidone.Approved
EthchlorvynolThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Etoperidone.Approved, Illicit, Withdrawn
EthosuximideThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Etoperidone.Approved
EthotoinThe risk or severity of adverse effects can be increased when Ethotoin is combined with Etoperidone.Approved
Ethyl biscoumacetateEtoperidone may increase the anticoagulant activities of Ethyl biscoumacetate.Withdrawn
Ethyl carbamateThe risk or severity of adverse effects can be increased when Ethyl carbamate is combined with Etoperidone.Withdrawn
Ethyl chlorideThe risk or severity of adverse effects can be increased when Ethyl chloride is combined with Etoperidone.Experimental, Investigational
Ethyl loflazepateThe risk or severity of adverse effects can be increased when Ethyl loflazepate is combined with Etoperidone.Approved, Illicit
EthylmorphineEthylmorphine may increase the serotonergic activities of Etoperidone.Approved, Illicit
EtidocaineThe risk or severity of adverse effects can be increased when Etidocaine is combined with Etoperidone.Approved
EtifoxineThe risk or severity of adverse effects can be increased when Etifoxine is combined with Etoperidone.Investigational, Withdrawn
EtizolamThe risk or severity of adverse effects can be increased when Etizolam is combined with Etoperidone.Approved
EtodolacEtoperidone may increase the antiplatelet activities of Etodolac.Approved, Investigational, Vet Approved
EtomidateThe risk or severity of adverse effects can be increased when Etomidate is combined with Etoperidone.Approved
EtoricoxibEtoperidone may increase the antiplatelet activities of Etoricoxib.Approved, Investigational
EtorphineEtorphine may increase the serotonergic activities of Etoperidone.Illicit, Vet Approved
ExenatideEtoperidone may increase the hypoglycemic activities of Exenatide.Approved, Investigational
EzogabineThe risk or severity of adverse effects can be increased when Ezogabine is combined with Etoperidone.Approved
FelbamateThe risk or severity of adverse effects can be increased when Felbamate is combined with Etoperidone.Approved
FencamfamineThe risk or severity of adverse effects can be increased when Fencamfamine is combined with Etoperidone.Approved, Illicit, Withdrawn
FenfluramineEtoperidone may increase the serotonergic activities of Fenfluramine.Illicit, Investigational, Withdrawn
FentanylFentanyl may increase the serotonergic activities of Etoperidone.Approved, Illicit, Investigational, Vet Approved
FexofenadineThe risk or severity of adverse effects can be increased when Fexofenadine is combined with Etoperidone.Approved
FlibanserinThe risk or severity of adverse effects can be increased when Flibanserin is combined with Etoperidone.Approved
FluanisoneThe risk or severity of adverse effects can be increased when Fluanisone is combined with Etoperidone.Experimental
FludiazepamThe risk or severity of adverse effects can be increased when Fludiazepam is combined with Etoperidone.Approved, Illicit
FluindioneEtoperidone may increase the anticoagulant activities of Fluindione.Investigational
FlunarizineThe risk or severity of adverse effects can be increased when Flunarizine is combined with Etoperidone.Approved
FlunitrazepamThe risk or severity of adverse effects can be increased when Flunitrazepam is combined with Etoperidone.Approved, Illicit
FluoxetineEtoperidone may increase the serotonergic activities of Fluoxetine.Approved, Vet Approved
FlupentixolThe risk or severity of adverse effects can be increased when Flupentixol is combined with Etoperidone.Approved, Withdrawn
FluphenazineThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Etoperidone.Approved
FlurazepamThe risk or severity of adverse effects can be increased when Flurazepam is combined with Etoperidone.Approved, Illicit
FluspirileneThe risk or severity of adverse effects can be increased when Fluspirilene is combined with Etoperidone.Approved, Investigational
Fluticasone propionateThe risk or severity of adverse effects can be increased when Fluticasone propionate is combined with Etoperidone.Approved
FluvoxamineEtoperidone may increase the serotonergic activities of Fluvoxamine.Approved, Investigational
FosphenytoinThe risk or severity of adverse effects can be increased when Fosphenytoin is combined with Etoperidone.Approved
FospropofolThe risk or severity of adverse effects can be increased when Fospropofol is combined with Etoperidone.Approved, Illicit, Investigational
FurazolidoneFurazolidone may increase the serotonergic activities of Etoperidone.Approved, Investigational, Vet Approved
GabapentinThe risk or severity of adverse effects can be increased when Gabapentin is combined with Etoperidone.Approved, Investigational
Gabapentin EnacarbilThe risk or severity of adverse effects can be increased when Gabapentin Enacarbil is combined with Etoperidone.Approved
GalantamineThe metabolism of Galantamine can be decreased when combined with Etoperidone.Approved
Gamma Hydroxybutyric AcidThe risk or severity of adverse effects can be increased when Gamma Hydroxybutyric Acid is combined with Etoperidone.Approved, Illicit, Investigational
GepironeThe risk or severity of adverse effects can be increased when Gepirone is combined with Etoperidone.Investigational
GliclazideEtoperidone may increase the hypoglycemic activities of Gliclazide.Approved
GlimepirideEtoperidone may increase the hypoglycemic activities of Glimepiride.Approved
GlipizideEtoperidone may increase the hypoglycemic activities of Glipizide.Approved
GlutethimideThe risk or severity of adverse effects can be increased when Glutethimide is combined with Etoperidone.Approved, Illicit
GlyburideEtoperidone may increase the hypoglycemic activities of Glyburide.Approved
GuanfacineThe risk or severity of adverse effects can be increased when Guanfacine is combined with Etoperidone.Approved, Investigational
HalazepamThe risk or severity of adverse effects can be increased when Halazepam is combined with Etoperidone.Approved, Illicit, Withdrawn
HaloperidolThe risk or severity of adverse effects can be increased when Haloperidol is combined with Etoperidone.Approved
HalothaneThe risk or severity of adverse effects can be increased when Halothane is combined with Etoperidone.Approved, Vet Approved
HarmalineThe risk or severity of adverse effects can be increased when Etoperidone is combined with Harmaline.Experimental
HeroinHeroin may increase the serotonergic activities of Etoperidone.Approved, Illicit, Investigational
HexobarbitalThe risk or severity of adverse effects can be increased when Hexobarbital is combined with Etoperidone.Approved
HydracarbazineHydracarbazine may increase the serotonergic activities of Etoperidone.Experimental
HydrochlorothiazideEtoperidone may increase the hyponatremic activities of Hydrochlorothiazide.Approved, Vet Approved
HydrocodoneHydrocodone may increase the serotonergic activities of Etoperidone.Approved, Illicit
HydroflumethiazideEtoperidone may increase the hyponatremic activities of Hydroflumethiazide.Approved, Investigational
HydromorphoneHydromorphone may increase the serotonergic activities of Etoperidone.Approved, Illicit
HydroxyzineThe risk or severity of adverse effects can be increased when Hydroxyzine is combined with Etoperidone.Approved
IloperidoneThe risk or severity of adverse effects can be increased when Iloperidone is combined with Etoperidone.Approved
ImipramineThe risk or severity of adverse effects can be increased when Imipramine is combined with Etoperidone.Approved
IndalpineEtoperidone may increase the serotonergic activities of Indalpine.Investigational, Withdrawn
IndapamideEtoperidone may increase the hyponatremic activities of Indapamide.Approved
IndenololThe serum concentration of Indenolol can be increased when it is combined with Etoperidone.Withdrawn
IndiplonThe risk or severity of adverse effects can be increased when Indiplon is combined with Etoperidone.Investigational
Insulin AspartEtoperidone may increase the hypoglycemic activities of Insulin Aspart.Approved
Insulin DetemirEtoperidone may increase the hypoglycemic activities of Insulin Detemir.Approved
Insulin GlargineEtoperidone may increase the hypoglycemic activities of Insulin Glargine.Approved
Insulin GlulisineEtoperidone may increase the hypoglycemic activities of Insulin Glulisine.Approved
Insulin HumanEtoperidone may increase the hypoglycemic activities of Insulin Human.Approved, Investigational
Insulin LisproEtoperidone may increase the hypoglycemic activities of Insulin Lispro.Approved
IobenguaneThe therapeutic efficacy of Iobenguane can be decreased when used in combination with Etoperidone.Approved, Investigational
Ioflupane I-123Etoperidone may decrease effectiveness of Ioflupane I-123 as a diagnostic agent.Approved
IproclozideIproclozide may increase the serotonergic activities of Etoperidone.Withdrawn
IproniazidIproniazid may increase the serotonergic activities of Etoperidone.Withdrawn
IsocarboxazidIsocarboxazid may increase the serotonergic activities of Etoperidone.Approved
IsofluraneThe risk or severity of adverse effects can be increased when Isoflurane is combined with Etoperidone.Approved, Vet Approved
KetamineThe risk or severity of adverse effects can be increased when Ketamine is combined with Etoperidone.Approved, Vet Approved
KetazolamThe risk or severity of adverse effects can be increased when Ketazolam is combined with Etoperidone.Approved
KetobemidoneKetobemidone may increase the serotonergic activities of Etoperidone.Approved, Investigational
L-TryptophanL-Tryptophan may increase the serotonergic activities of Etoperidone.Approved, Nutraceutical, Withdrawn
LabetalolThe serum concentration of Labetalol can be increased when it is combined with Etoperidone.Approved
LamotrigineThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Etoperidone.Approved, Investigational
LandiololThe serum concentration of Landiolol can be increased when it is combined with Etoperidone.Investigational
LevetiracetamThe risk or severity of adverse effects can be increased when Levetiracetam is combined with Etoperidone.Approved, Investigational
LevobunololThe serum concentration of Levobunolol can be increased when it is combined with Etoperidone.Approved
LevobupivacaineThe risk or severity of adverse effects can be increased when Levobupivacaine is combined with Etoperidone.Approved, Investigational
LevocabastineThe risk or severity of adverse effects can be increased when Levocabastine is combined with Etoperidone.Approved
LevocetirizineThe risk or severity of adverse effects can be increased when Levocetirizine is combined with Etoperidone.Approved
LevodopaThe risk or severity of adverse effects can be increased when Levodopa is combined with Etoperidone.Approved
Levomethadyl AcetateLevomethadyl Acetate may increase the serotonergic activities of Etoperidone.Approved, Investigational
LevomilnacipranEtoperidone may increase the serotonergic activities of Levomilnacipran.Approved
LevorphanolLevorphanol may increase the serotonergic activities of Etoperidone.Approved
LevothyroxineThe therapeutic efficacy of Levothyroxine can be decreased when used in combination with Etoperidone.Approved
LidocaineThe risk or severity of adverse effects can be increased when Lidocaine is combined with Etoperidone.Approved, Vet Approved
LinezolidLinezolid may increase the serotonergic activities of Etoperidone.Approved, Investigational
LiothyronineThe therapeutic efficacy of Liothyronine can be decreased when used in combination with Etoperidone.Approved, Vet Approved
LiotrixThe therapeutic efficacy of Liotrix can be decreased when used in combination with Etoperidone.Approved
LiraglutideEtoperidone may increase the hypoglycemic activities of Liraglutide.Approved
LithiumLithium may increase the serotonergic activities of Etoperidone.Approved
LofentanilLofentanil may increase the serotonergic activities of Etoperidone.Illicit
LoprazolamThe risk or severity of adverse effects can be increased when Loprazolam is combined with Etoperidone.Experimental
LoratadineThe risk or severity of adverse effects can be increased when Loratadine is combined with Etoperidone.Approved
LorazepamThe risk or severity of adverse effects can be increased when Lorazepam is combined with Etoperidone.Approved
LormetazepamThe risk or severity of adverse effects can be increased when Lormetazepam is combined with Etoperidone.Approved
LoxapineThe risk or severity of adverse effects can be increased when Loxapine is combined with Etoperidone.Approved
LumiracoxibEtoperidone may increase the antiplatelet activities of Lumiracoxib.Approved, Investigational
LurasidoneThe risk or severity of adverse effects can be increased when Lurasidone is combined with Etoperidone.Approved
Magnesium SulfateThe risk or severity of adverse effects can be increased when Magnesium Sulfate is combined with Etoperidone.Approved, Vet Approved
MaprotilineThe risk or severity of adverse effects can be increased when Maprotiline is combined with Etoperidone.Approved
MebanazineMebanazine may increase the serotonergic activities of Etoperidone.Withdrawn
MebicarThe risk or severity of adverse effects can be increased when Mebicar is combined with Etoperidone.Experimental
MecaserminEtoperidone may increase the hypoglycemic activities of Mecasermin.Approved, Investigational
MeclizineThe risk or severity of adverse effects can be increased when Meclizine is combined with Etoperidone.Approved
MedazepamThe risk or severity of adverse effects can be increased when Medazepam is combined with Etoperidone.Experimental
MedetomidineThe risk or severity of adverse effects can be increased when Medetomidine is combined with Etoperidone.Vet Approved
MelatoninThe risk or severity of adverse effects can be increased when Melatonin is combined with Etoperidone.Approved, Nutraceutical, Vet Approved
MelperoneThe risk or severity of adverse effects can be increased when Melperone is combined with Etoperidone.Approved, Investigational
MepindololThe serum concentration of Mepindolol can be increased when it is combined with Etoperidone.Experimental
MepivacaineThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Etoperidone.Approved, Vet Approved
MeprobamateThe risk or severity of adverse effects can be increased when Meprobamate is combined with Etoperidone.Approved, Illicit
MeptazinolMeptazinol may increase the serotonergic activities of Etoperidone.Experimental
MesoridazineThe risk or severity of adverse effects can be increased when Mesoridazine is combined with Etoperidone.Approved, Investigational
MetaxaloneThe risk or severity of adverse effects can be increased when Metaxalone is combined with Etoperidone.Approved
MetforminEtoperidone may increase the hypoglycemic activities of Metformin.Approved
MethadoneThe metabolism of Methadone can be decreased when combined with Etoperidone.Approved
Methadyl AcetateMethadyl Acetate may increase the serotonergic activities of Etoperidone.Approved, Illicit
MethapyrileneThe risk or severity of adverse effects can be increased when Methapyrilene is combined with Etoperidone.Withdrawn
MethaqualoneThe risk or severity of adverse effects can be increased when Methaqualone is combined with Etoperidone.Illicit, Withdrawn
MethocarbamolThe risk or severity of adverse effects can be increased when Methocarbamol is combined with Etoperidone.Approved, Vet Approved
MethohexitalThe risk or severity of adverse effects can be increased when Methohexital is combined with Etoperidone.Approved
MethotrimeprazineThe risk or severity of adverse effects can be increased when Methotrimeprazine is combined with Etoperidone.Approved
MethoxyfluraneThe risk or severity of adverse effects can be increased when Methoxyflurane is combined with Etoperidone.Approved, Investigational, Vet Approved
MethsuximideThe risk or severity of adverse effects can be increased when Methsuximide is combined with Etoperidone.Approved
MethyclothiazideEtoperidone may increase the hyponatremic activities of Methyclothiazide.Approved
MethylecgonineThe risk or severity of adverse effects can be increased when Methylecgonine is combined with Etoperidone.Experimental
Methylene blueEtoperidone may increase the serotonergic activities of Methylene blue.Approved, Investigational
MethylphenobarbitalThe risk or severity of adverse effects can be increased when Methylphenobarbital is combined with Etoperidone.Approved
MetipranololThe serum concentration of Metipranolol can be increased when it is combined with Etoperidone.Approved
MetoclopramideThe risk or severity of adverse effects can be increased when Metoclopramide is combined with Etoperidone.Approved, Investigational
MetolazoneEtoperidone may increase the hyponatremic activities of Metolazone.Approved
MetoprololThe serum concentration of Metoprolol can be increased when it is combined with Etoperidone.Approved, Investigational
MetyrosineThe risk or severity of adverse effects can be increased when Metyrosine is combined with Etoperidone.Approved
MexiletineThe metabolism of Mexiletine can be decreased when combined with Etoperidone.Approved
MidazolamThe risk or severity of adverse effects can be increased when Midazolam is combined with Etoperidone.Approved, Illicit
MifepristoneEtoperidone may increase the hypoglycemic activities of Mifepristone.Approved, Investigational
MiglitolEtoperidone may increase the hypoglycemic activities of Miglitol.Approved
MilnacipranEtoperidone may increase the serotonergic activities of Milnacipran.Approved
MinaprineMinaprine may increase the serotonergic activities of Etoperidone.Approved
MirtazapineThe risk or severity of adverse effects can be increased when Mirtazapine is combined with Etoperidone.Approved
MoclobemideMoclobemide may increase the serotonergic activities of Etoperidone.Approved
MolindoneThe risk or severity of adverse effects can be increased when Molindone is combined with Etoperidone.Approved
MorphineMorphine may increase the serotonergic activities of Etoperidone.Approved, Investigational
NabiloneThe risk or severity of adverse effects can be increased when Nabilone is combined with Etoperidone.Approved, Investigational
NabumetoneEtoperidone may increase the antiplatelet activities of Nabumetone.Approved
NadololThe serum concentration of Nadolol can be increased when it is combined with Etoperidone.Approved
NalbuphineNalbuphine may increase the serotonergic activities of Etoperidone.Approved
NateglinideEtoperidone may increase the hypoglycemic activities of Nateglinide.Approved, Investigational
NebivololThe serum concentration of Nebivolol can be increased when it is combined with Etoperidone.Approved, Investigational
NefazodoneEtoperidone may increase the serotonergic activities of Nefazodone.Approved, Withdrawn
NialamideNialamide may increase the serotonergic activities of Etoperidone.Withdrawn
NicomorphineNicomorphine may increase the serotonergic activities of Etoperidone.Experimental
NitrazepamThe risk or severity of adverse effects can be increased when Nitrazepam is combined with Etoperidone.Approved
Nitrous oxideThe risk or severity of adverse effects can be increased when Nitrous oxide is combined with Etoperidone.Approved, Vet Approved
NorfluraneThe risk or severity of adverse effects can be increased when Norflurane is combined with Etoperidone.Investigational
NormethadoneNormethadone may increase the serotonergic activities of Etoperidone.Approved, Illicit
NortriptylineThe risk or severity of adverse effects can be increased when Nortriptyline is combined with Etoperidone.Approved
OctamoxinOctamoxin may increase the serotonergic activities of Etoperidone.Withdrawn
OlanzapineEtoperidone may increase the serotonergic activities of Olanzapine.Approved, Investigational
OlopatadineThe risk or severity of adverse effects can be increased when Olopatadine is combined with Etoperidone.Approved
OndansetronThe risk or severity of adverse effects can be increased when Ondansetron is combined with Etoperidone.Approved
OpiumOpium may increase the serotonergic activities of Etoperidone.Approved, Illicit
OrphenadrineThe risk or severity of adverse effects can be increased when Orphenadrine is combined with Etoperidone.Approved
OsanetantThe risk or severity of adverse effects can be increased when Osanetant is combined with Etoperidone.Investigational
OxazepamThe risk or severity of adverse effects can be increased when Oxazepam is combined with Etoperidone.Approved
OxethazaineThe risk or severity of adverse effects can be increased when Oxethazaine is combined with Etoperidone.Approved, Investigational
OxprenololThe serum concentration of Oxprenolol can be increased when it is combined with Etoperidone.Approved
OxybuprocaineThe risk or severity of adverse effects can be increased when Oxybuprocaine is combined with Etoperidone.Approved
OxycodoneOxycodone may increase the serotonergic activities of Etoperidone.Approved, Illicit, Investigational
OxymorphoneOxymorphone may increase the serotonergic activities of Etoperidone.Approved, Investigational, Vet Approved
PaliperidoneThe risk or severity of adverse effects can be increased when Paliperidone is combined with Etoperidone.Approved
ParaldehydeThe risk or severity of adverse effects can be increased when Paraldehyde is combined with Etoperidone.Approved, Investigational
ParecoxibEtoperidone may increase the antiplatelet activities of Parecoxib.Approved
PargylinePargyline may increase the serotonergic activities of Etoperidone.Approved
ParoxetineEtoperidone may increase the serotonergic activities of Paroxetine.Approved, Investigational
PenbutololThe serum concentration of Penbutolol can be increased when it is combined with Etoperidone.Approved, Investigational
PenfluridolThe risk or severity of adverse effects can be increased when Penfluridol is combined with Etoperidone.Experimental
PentamidineEtoperidone may increase the hypoglycemic activities of Pentamidine.Approved
PentazocinePentazocine may increase the serotonergic activities of Etoperidone.Approved, Vet Approved
PentobarbitalThe risk or severity of adverse effects can be increased when Pentobarbital is combined with Etoperidone.Approved, Vet Approved
PerampanelThe risk or severity of adverse effects can be increased when Perampanel is combined with Etoperidone.Approved
PerazineThe risk or severity of adverse effects can be increased when Perazine is combined with Etoperidone.Investigational
PerospironeThe risk or severity of adverse effects can be increased when Perospirone is combined with Etoperidone.Approved
PerphenazineThe risk or severity of adverse effects can be increased when Perphenazine is combined with Etoperidone.Approved
PethidinePethidine may increase the serotonergic activities of Etoperidone.Approved
PhenazocinePhenazocine may increase the serotonergic activities of Etoperidone.Experimental
PhenelzinePhenelzine may increase the serotonergic activities of Etoperidone.Approved
PhenibutThe risk or severity of adverse effects can be increased when Phenibut is combined with Etoperidone.Experimental
PhenindioneEtoperidone may increase the anticoagulant activities of Phenindione.Approved, Investigational
PheniprazinePheniprazine may increase the serotonergic activities of Etoperidone.Withdrawn
PhenobarbitalThe risk or severity of adverse effects can be increased when Phenobarbital is combined with Etoperidone.Approved
PhenoperidinePhenoperidine may increase the serotonergic activities of Etoperidone.Experimental
PhenoxyethanolThe risk or severity of adverse effects can be increased when Phenoxyethanol is combined with Etoperidone.Approved
PhenoxypropazinePhenoxypropazine may increase the serotonergic activities of Etoperidone.Withdrawn
PhenprocoumonEtoperidone may increase the anticoagulant activities of Phenprocoumon.Approved, Investigational
PhenytoinThe risk or severity of adverse effects can be increased when Phenytoin is combined with Etoperidone.Approved, Vet Approved
PimozideThe risk or severity of adverse effects can be increased when Etoperidone is combined with Pimozide.Approved
PindololThe serum concentration of Pindolol can be increased when it is combined with Etoperidone.Approved
PioglitazoneEtoperidone may increase the hypoglycemic activities of Pioglitazone.Approved, Investigational
PipamperoneThe risk or severity of adverse effects can be increased when Pipamperone is combined with Etoperidone.Approved, Investigational
PipotiazineThe risk or severity of adverse effects can be increased when Pipotiazine is combined with Etoperidone.Approved, Investigational
PiritramidePiritramide may increase the serotonergic activities of Etoperidone.Investigational
PirlindolePirlindole may increase the serotonergic activities of Etoperidone.Approved
PivhydrazinePivhydrazine may increase the serotonergic activities of Etoperidone.Withdrawn
PizotifenThe risk or severity of adverse effects can be increased when Pizotifen is combined with Etoperidone.Approved
Platelet Activating FactorThe serum concentration of Platelet Activating Factor can be increased when it is combined with Etoperidone.Experimental
PolythiazideEtoperidone may increase the hyponatremic activities of Polythiazide.Approved
PomalidomideThe risk or severity of adverse effects can be increased when Pomalidomide is combined with Etoperidone.Approved
PractololThe serum concentration of Practolol can be increased when it is combined with Etoperidone.Approved
PramlintideEtoperidone may increase the hypoglycemic activities of Pramlintide.Approved, Investigational
PramocaineThe risk or severity of adverse effects can be increased when Pramocaine is combined with Etoperidone.Approved
PrazepamThe risk or severity of adverse effects can be increased when Prazepam is combined with Etoperidone.Approved, Illicit
PregabalinThe risk or severity of adverse effects can be increased when Pregabalin is combined with Etoperidone.Approved, Illicit, Investigational
PrilocaineThe risk or severity of adverse effects can be increased when Prilocaine is combined with Etoperidone.Approved
PrimidoneThe risk or severity of adverse effects can be increased when Primidone is combined with Etoperidone.Approved, Vet Approved
ProcaineThe risk or severity of adverse effects can be increased when Procaine is combined with Etoperidone.Approved, Investigational, Vet Approved
ProcarbazineThe risk or severity of adverse effects can be increased when Etoperidone is combined with Procarbazine.Approved
ProchlorperazineThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Etoperidone.Approved, Vet Approved
PromazineThe risk or severity of adverse effects can be increased when Promazine is combined with Etoperidone.Approved, Vet Approved
PromethazineThe risk or severity of adverse effects can be increased when Promethazine is combined with Etoperidone.Approved
PropanididThe risk or severity of adverse effects can be increased when Propanidid is combined with Etoperidone.Experimental
ProparacaineThe risk or severity of adverse effects can be increased when Proparacaine is combined with Etoperidone.Approved, Vet Approved
PropofolThe risk or severity of adverse effects can be increased when Propofol is combined with Etoperidone.Approved, Investigational, Vet Approved
PropoxycaineThe risk or severity of adverse effects can be increased when Propoxycaine is combined with Etoperidone.Approved
PropranololThe serum concentration of Propranolol can be increased when it is combined with Etoperidone.Approved, Investigational
ProtriptylineThe risk or severity of adverse effects can be increased when Protriptyline is combined with Etoperidone.Approved
ProxibarbalThe risk or severity of adverse effects can be increased when Proxibarbal is combined with Etoperidone.Experimental
PSD502The risk or severity of adverse effects can be increased when PSD502 is combined with Etoperidone.Investigational
QuazepamThe risk or severity of adverse effects can be increased when Quazepam is combined with Etoperidone.Approved, Illicit
QuetiapineThe risk or severity of adverse effects can be increased when Quetiapine is combined with Etoperidone.Approved
QuinethazoneEtoperidone may increase the hyponatremic activities of Quinethazone.Approved
QuinineEtoperidone may increase the hypoglycemic activities of Quinine.Approved
QuinisocaineThe risk or severity of adverse effects can be increased when Quinisocaine is combined with Etoperidone.Experimental
RacloprideThe risk or severity of adverse effects can be increased when Raclopride is combined with Etoperidone.Investigational
RamelteonThe risk or severity of adverse effects can be increased when Ramelteon is combined with Etoperidone.Approved, Investigational
RasagilineRasagiline may increase the serotonergic activities of Etoperidone.Approved
RemifentanilRemifentanil may increase the serotonergic activities of Etoperidone.Approved
RemoxiprideThe risk or severity of adverse effects can be increased when Remoxipride is combined with Etoperidone.Approved, Withdrawn
RepaglinideEtoperidone may increase the hypoglycemic activities of Repaglinide.Approved, Investigational
ReserpineThe risk or severity of adverse effects can be increased when Reserpine is combined with Etoperidone.Approved, Investigational
RisperidoneThe metabolism of Risperidone can be decreased when combined with Etoperidone.Approved, Investigational
RitanserinThe risk or severity of adverse effects can be increased when Ritanserin is combined with Etoperidone.Investigational
RofecoxibEtoperidone may increase the antiplatelet activities of Rofecoxib.Investigational, Withdrawn
RomifidineThe risk or severity of adverse effects can be increased when Romifidine is combined with Etoperidone.Vet Approved
RopivacaineThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Etoperidone.Approved
RosiglitazoneEtoperidone may increase the hypoglycemic activities of Rosiglitazone.Approved, Investigational
SafrazineSafrazine may increase the serotonergic activities of Etoperidone.Withdrawn
SaxagliptinEtoperidone may increase the hypoglycemic activities of Saxagliptin.Approved
ScopolamineThe risk or severity of adverse effects can be increased when Scopolamine is combined with Etoperidone.Approved
SecobarbitalThe risk or severity of adverse effects can be increased when Secobarbital is combined with Etoperidone.Approved, Vet Approved
SelegilineSelegiline may increase the serotonergic activities of Etoperidone.Approved, Investigational, Vet Approved
SepranoloneThe risk or severity of adverse effects can be increased when Sepranolone is combined with Etoperidone.Investigational
SertindoleThe risk or severity of adverse effects can be increased when Sertindole is combined with Etoperidone.Approved, Investigational, Withdrawn
SertralineEtoperidone may increase the serotonergic activities of Sertraline.Approved
SevofluraneThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Etoperidone.Approved, Vet Approved
SitagliptinEtoperidone may increase the hypoglycemic activities of Sitagliptin.Approved, Investigational
Sodium oxybateThe risk or severity of adverse effects can be increased when Sodium oxybate is combined with Etoperidone.Approved
SotalolThe serum concentration of Sotalol can be increased when it is combined with Etoperidone.Approved
StiripentolThe risk or severity of adverse effects can be increased when Stiripentol is combined with Etoperidone.Approved
SufentanilSufentanil may increase the serotonergic activities of Etoperidone.Approved, Investigational
SulfadiazineEtoperidone may increase the hypoglycemic activities of Sulfadiazine.Approved, Vet Approved
SulfamethoxazoleEtoperidone may increase the hypoglycemic activities of Sulfamethoxazole.Approved
SulfisoxazoleEtoperidone may increase the hypoglycemic activities of Sulfisoxazole.Approved, Vet Approved
SulpirideThe risk or severity of adverse effects can be increased when Sulpiride is combined with Etoperidone.Approved, Investigational
SultoprideThe risk or severity of adverse effects can be increased when Sultopride is combined with Etoperidone.Experimental
SunitinibEtoperidone may increase the hypoglycemic activities of Sunitinib.Approved, Investigational
SuvorexantThe risk or severity of adverse effects can be increased when Suvorexant is combined with Etoperidone.Approved
TalinololThe serum concentration of Talinolol can be increased when it is combined with Etoperidone.Investigational
TandospironeThe risk or severity of adverse effects can be increased when Tandospirone is combined with Etoperidone.Investigational
TapentadolTapentadol may increase the serotonergic activities of Etoperidone.Approved
TasimelteonThe risk or severity of adverse effects can be increased when Tasimelteon is combined with Etoperidone.Approved
TemazepamThe risk or severity of adverse effects can be increased when Temazepam is combined with Etoperidone.Approved
TertatololThe serum concentration of Tertatolol can be increased when it is combined with Etoperidone.Experimental
TetrabenazineThe risk or severity of adverse effects can be increased when Tetrabenazine is combined with Etoperidone.Approved
TetracaineThe risk or severity of adverse effects can be increased when Tetracaine is combined with Etoperidone.Approved, Vet Approved
TetrahydropalmatineThe risk or severity of adverse effects can be increased when Tetrahydropalmatine is combined with Etoperidone.Investigational
TetrodotoxinThe risk or severity of adverse effects can be increased when Tetrodotoxin is combined with Etoperidone.Investigational
ThalidomideThe risk or severity of adverse effects can be increased when Thalidomide is combined with Etoperidone.Approved, Investigational, Withdrawn
ThiamylalThe risk or severity of adverse effects can be increased when Thiamylal is combined with Etoperidone.Approved, Vet Approved
ThiopentalThe risk or severity of adverse effects can be increased when Thiopental is combined with Etoperidone.Approved, Vet Approved
ThioridazineThe risk or severity of adverse effects can be increased when Thioridazine is combined with Etoperidone.Approved, Withdrawn
ThiothixeneThe risk or severity of adverse effects can be increased when Thiothixene is combined with Etoperidone.Approved
Thyroid, porcineThe therapeutic efficacy of Thyroid, porcine can be decreased when used in combination with Etoperidone.Approved
TiagabineThe risk or severity of adverse effects can be increased when Tiagabine is combined with Etoperidone.Approved
TiaprideThe risk or severity of adverse effects can be increased when Tiapride is combined with Etoperidone.Approved, Investigational
TiletamineThe risk or severity of adverse effects can be increased when Tiletamine is combined with Etoperidone.Vet Approved
TilidineTilidine may increase the serotonergic activities of Etoperidone.Experimental
TimololThe serum concentration of Timolol can be increased when it is combined with Etoperidone.Approved
TioclomarolEtoperidone may increase the anticoagulant activities of Tioclomarol.Experimental
TizanidineThe risk or severity of adverse effects can be increased when Tizanidine is combined with Etoperidone.Approved
TolazamideEtoperidone may increase the hypoglycemic activities of Tolazamide.Approved
TolbutamideEtoperidone may increase the hypoglycemic activities of Tolbutamide.Approved
TolcaponeThe risk or severity of adverse effects can be increased when Tolcapone is combined with Etoperidone.Approved, Withdrawn
ToloxatoneToloxatone may increase the serotonergic activities of Etoperidone.Approved
TopiramateThe risk or severity of adverse effects can be increased when Topiramate is combined with Etoperidone.Approved
TramadolEtoperidone may increase the neuroexcitatory activities of Tramadol.Approved, Investigational
Trans-2-PhenylcyclopropylamineThe risk or severity of adverse effects can be increased when Trans-2-Phenylcyclopropylamine is combined with Etoperidone.Experimental
TranylcypromineThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Etoperidone.Approved
TrazodoneEtoperidone may increase the serotonergic activities of Trazodone.Approved, Investigational
TriazolamThe risk or severity of adverse effects can be increased when Triazolam is combined with Etoperidone.Approved
Tricaine methanesulfonateThe risk or severity of adverse effects can be increased when Tricaine methanesulfonate is combined with Etoperidone.Vet Approved
TrichlormethiazideEtoperidone may increase the hyponatremic activities of Trichlormethiazide.Approved, Vet Approved
TrichloroethyleneThe risk or severity of adverse effects can be increased when Trichloroethylene is combined with Etoperidone.Approved
TrifluoperazineThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Etoperidone.Approved
TrifluperidolThe risk or severity of adverse effects can be increased when Trifluperidol is combined with Etoperidone.Experimental
TriflupromazineThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Etoperidone.Approved, Vet Approved
TrimipramineThe risk or severity of adverse effects can be increased when Trimipramine is combined with Etoperidone.Approved
TriprolidineThe risk or severity of adverse effects can be increased when Triprolidine is combined with Etoperidone.Approved
ValdecoxibEtoperidone may increase the antiplatelet activities of Valdecoxib.Investigational, Withdrawn
Valproic AcidThe risk or severity of adverse effects can be increased when Valproic Acid is combined with Etoperidone.Approved, Investigational
VemurafenibThe risk or severity of QTc prolongation can be increased when Vemurafenib is combined with Etoperidone.Approved
VeraliprideThe risk or severity of adverse effects can be increased when Veralipride is combined with Etoperidone.Experimental
VigabatrinThe risk or severity of adverse effects can be increased when Vigabatrin is combined with Etoperidone.Approved
VilazodoneEtoperidone may increase the serotonergic activities of Vilazodone.Approved
Vinyl etherThe risk or severity of adverse effects can be increased when Vinyl ether is combined with Etoperidone.Experimental
VortioxetineEtoperidone may increase the serotonergic activities of Vortioxetine.Approved
WarfarinEtoperidone may increase the anticoagulant activities of Warfarin.Approved
XenonThe risk or severity of adverse effects can be increased when Xenon is combined with Etoperidone.Experimental
XylazineThe risk or severity of adverse effects can be increased when Xylazine is combined with Etoperidone.Vet Approved
ZaleplonThe risk or severity of adverse effects can be increased when Zaleplon is combined with Etoperidone.Approved, Illicit, Investigational
ZiconotideThe risk or severity of adverse effects can be increased when Ziconotide is combined with Etoperidone.Approved
ZimelidineEtoperidone may increase the serotonergic activities of Zimelidine.Withdrawn
ZiprasidoneThe risk or severity of adverse effects can be increased when Ziprasidone is combined with Etoperidone.Approved
ZolazepamThe risk or severity of adverse effects can be increased when Zolazepam is combined with Etoperidone.Vet Approved
ZolpidemThe risk or severity of adverse effects can be increased when Zolpidem is combined with Etoperidone.Approved
ZonisamideThe risk or severity of adverse effects can be increased when Zonisamide is combined with Etoperidone.Approved, Investigational
ZopicloneThe risk or severity of adverse effects can be increased when Zopiclone is combined with Etoperidone.Approved
ZotepineThe risk or severity of adverse effects can be increased when Zotepine is combined with Etoperidone.Approved, Investigational
ZuclopenthixolThe risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Etoperidone.Approved, Investigational
Food Interactions
Not Available

References

General References
  1. Tatsumi M, Groshan K, Blakely RD, Richelson E: Pharmacological profile of antidepressants and related compounds at human monoamine transporters. Eur J Pharmacol. 1997 Dec 11;340(2-3):249-58. [PubMed:9537821]
  2. Cusack B, Nelson A, Richelson E: Binding of antidepressants to human brain receptors: focus on newer generation compounds. Psychopharmacology (Berl). 1994 May;114(4):559-65. [PubMed:7855217]
  3. Costa A, Martignoni E, Blandini F, Petraglia F, Genazzani AR, Nappi G: Effects of etoperidone on sympathetic and pituitary-adrenal responses to diverse stressors in humans. Clin Neuropharmacol. 1993 Apr;16(2):127-38. [PubMed:8386590]
  4. Caldwell GW, Wu WN, Masucci JA: Evaluation of the absorption, excretion and metabolism of [14C] etoperidone in man. Xenobiotica. 2001 Nov;31(11):823-39. doi: 10.1080/00498250110091758 . [PubMed:11765144]
  5. Lisciani R, Baldini A, Benedetti D, Campana A, Barcellona PS: Acute cardiovascular toxicity of trazodone, etoperidone and imipramine in rats. Toxicology. 1978 Jun;10(2):151-8. [PubMed:684760]
  6. Ellis G.P. and West G.B. (1986). Progress in Medicinal Chemistry Volume 23 (pp. 159). Elsevier.
  7. Morrison-Valfre M. (2016). Foundations of Mental Health Care (pp. 245). Elsevier .
  8. Taylor and Francis (2000). Index Nominum 2000: International drug directory. Swiss Pharmaceutical Society.
  9. O'Brien R.A. (1986). Receptor Binding in drug research. Marcel Dekker Inc..
  10. Barceloux D.G. (2012). Medical toxicology of drug abuse: Synthesized chemicals and psychoactive plants.. Wiley.
  11. Patents [Link]
  12. Patents [Link]
  13. Not in Pubmed [Link]
External Links
PubChem Compound
40589
PubChem Substance
310265102
ChemSpider
37083
BindingDB
82438
ChEBI
135589
ChEMBL
CHEMBL1743259
Wikipedia
Etoperidone
ATC Codes
N06AB09 — Etoperidone
MSDS
Download (79 KB)

Clinical Trials

Clinical Trials
Not Available

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Solid
Experimental Properties
PropertyValueSource
melting point (°C)197-198 ºC"Drugs - Synonyms and Properties", Ashgate Publishing Co.
boiling point (°C)499ºC at 760mmHg"Drugs - Synonyms and Properties", Ashgate Publishing Co.
Predicted Properties
PropertyValueSource
Water Solubility0.425 mg/mLALOGPS
logP2.81ALOGPS
logP3.37ChemAxon
logS-3ALOGPS
pKa (Strongest Basic)7.09ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count4ChemAxon
Hydrogen Donor Count0ChemAxon
Polar Surface Area42.39 Å2ChemAxon
Rotatable Bond Count7ChemAxon
Refractivity106.57 m3·mol-1ChemAxon
Polarizability42.23 Å3ChemAxon
Number of Rings3ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleYesChemAxon
Predicted ADMET features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available

Taxonomy

Description
This compound belongs to the class of organic compounds known as phenylpiperazines. These are compounds containing a phenylpiperazine skeleton, which consists of a piperazine bound to a phenyl group.
Kingdom
Organic compounds
Super Class
Organoheterocyclic compounds
Class
Diazinanes
Sub Class
Piperazines
Direct Parent
Phenylpiperazines
Alternative Parents
N-arylpiperazines / Dialkylarylamines / Aniline and substituted anilines / N-alkylpiperazines / Chlorobenzenes / Aryl chlorides / Triazoles / Heteroaromatic compounds / Trialkylamines / Azacyclic compounds
show 5 more
Substituents
Phenylpiperazine / N-arylpiperazine / Tertiary aliphatic/aromatic amine / Dialkylarylamine / Aniline or substituted anilines / Chlorobenzene / Halobenzene / N-alkylpiperazine / Benzenoid / Aryl halide
show 19 more
Molecular Framework
Aromatic heteromonocyclic compounds
External Descriptors
Not Available

Targets

Kind
Protein group
Organism
Human
Pharmacological action
Unknown
Actions
Antagonist
General Function
Protein heterodimerization activity
Specific Function
This alpha-adrenergic receptor mediates its action by association with G proteins that activate a phosphatidylinositol-calcium second messenger system. Its effect is mediated by G(q) and G(11) prot...

Components:
References
  1. Cusack B, Nelson A, Richelson E: Binding of antidepressants to human brain receptors: focus on newer generation compounds. Psychopharmacology (Berl). 1994 May;114(4):559-65. [PubMed:7855217]
Kind
Protein group
Organism
Human
Pharmacological action
Unknown
Actions
Antagonist
General Function
Thioesterase binding
Specific Function
Alpha-2 adrenergic receptors mediate the catecholamine-induced inhibition of adenylate cyclase through the action of G proteins. The rank order of potency for agonists of this receptor is oxymetazo...

Components:
References
  1. Cusack B, Nelson A, Richelson E: Binding of antidepressants to human brain receptors: focus on newer generation compounds. Psychopharmacology (Berl). 1994 May;114(4):559-65. [PubMed:7855217]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Antagonist
General Function
Potassium channel regulator activity
Specific Function
Dopamine receptor whose activity is mediated by G proteins which inhibit adenylyl cyclase.
Gene Name
DRD2
Uniprot ID
P14416
Uniprot Name
D(2) dopamine receptor
Molecular Weight
50618.91 Da
References
  1. Cusack B, Nelson A, Richelson E: Binding of antidepressants to human brain receptors: focus on newer generation compounds. Psychopharmacology (Berl). 1994 May;114(4):559-65. [PubMed:7855217]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Antagonist
General Function
Histamine receptor activity
Specific Function
In peripheral tissues, the H1 subclass of histamine receptors mediates the contraction of smooth muscles, increase in capillary permeability due to contraction of terminal venules, and catecholamin...
Gene Name
HRH1
Uniprot ID
P35367
Uniprot Name
Histamine H1 receptor
Molecular Weight
55783.61 Da
References
  1. Cusack B, Nelson A, Richelson E: Binding of antidepressants to human brain receptors: focus on newer generation compounds. Psychopharmacology (Berl). 1994 May;114(4):559-65. [PubMed:7855217]
Kind
Protein group
Organism
Human
Pharmacological action
Unknown
Actions
Antagonist
General Function
Phosphatidylinositol phospholipase c activity
Specific Function
The muscarinic acetylcholine receptor mediates various cellular responses, including inhibition of adenylate cyclase, breakdown of phosphoinositides and modulation of potassium channels through the...

Components:
References
  1. Cusack B, Nelson A, Richelson E: Binding of antidepressants to human brain receptors: focus on newer generation compounds. Psychopharmacology (Berl). 1994 May;114(4):559-65. [PubMed:7855217]
Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Antagonist
General Function
Virus receptor activity
Specific Function
G-protein coupled receptor for 5-hydroxytryptamine (serotonin). Also functions as a receptor for various drugs and psychoactive substances, including mescaline, psilocybin, 1-(2,5-dimethoxy-4-iodop...
Gene Name
HTR2A
Uniprot ID
P28223
Uniprot Name
5-hydroxytryptamine receptor 2A
Molecular Weight
52602.58 Da
References
  1. Cusack B, Nelson A, Richelson E: Binding of antidepressants to human brain receptors: focus on newer generation compounds. Psychopharmacology (Berl). 1994 May;114(4):559-65. [PubMed:7855217]
Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Agonist
General Function
Serotonin receptor activity
Specific Function
G-protein coupled receptor for 5-hydroxytryptamine (serotonin). Also functions as a receptor for various drugs and psychoactive substances, including ergot alkaloid derivatives, 1-2,5,-dimethoxy-4-...
Gene Name
HTR2C
Uniprot ID
P28335
Uniprot Name
5-hydroxytryptamine receptor 2C
Molecular Weight
51820.705 Da
References
  1. Cusack B, Nelson A, Richelson E: Binding of antidepressants to human brain receptors: focus on newer generation compounds. Psychopharmacology (Berl). 1994 May;114(4):559-65. [PubMed:7855217]

Transporters

Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Inhibitor
General Function
Serotonin:sodium symporter activity
Specific Function
Serotonin transporter whose primary function in the central nervous system involves the regulation of serotonergic signaling via transport of serotonin molecules from the synaptic cleft back into t...
Gene Name
SLC6A4
Uniprot ID
P31645
Uniprot Name
Sodium-dependent serotonin transporter
Molecular Weight
70324.165 Da
References
  1. Cusack B, Nelson A, Richelson E: Binding of antidepressants to human brain receptors: focus on newer generation compounds. Psychopharmacology (Berl). 1994 May;114(4):559-65. [PubMed:7855217]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Norepinephrine:sodium symporter activity
Specific Function
Amine transporter. Terminates the action of noradrenaline by its high affinity sodium-dependent reuptake into presynaptic terminals.
Gene Name
SLC6A2
Uniprot ID
P23975
Uniprot Name
Sodium-dependent noradrenaline transporter
Molecular Weight
69331.42 Da
References
  1. Cusack B, Nelson A, Richelson E: Binding of antidepressants to human brain receptors: focus on newer generation compounds. Psychopharmacology (Berl). 1994 May;114(4):559-65. [PubMed:7855217]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Monoamine transmembrane transporter activity
Specific Function
Amine transporter. Terminates the action of dopamine by its high affinity sodium-dependent reuptake into presynaptic terminals.
Gene Name
SLC6A3
Uniprot ID
Q01959
Uniprot Name
Sodium-dependent dopamine transporter
Molecular Weight
68494.255 Da
References
  1. Cusack B, Nelson A, Richelson E: Binding of antidepressants to human brain receptors: focus on newer generation compounds. Psychopharmacology (Berl). 1994 May;114(4):559-65. [PubMed:7855217]

Drug created on October 16, 2015 15:21 / Updated on December 01, 2017 17:37